OZTA Stock Overview
Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 4/6 |
Past Performance | 1/6 |
Financial Health | 2/6 |
Dividends | 0/6 |
Grifols, S.A. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €8.75 |
52 Week High | €15.37 |
52 Week Low | €6.59 |
Beta | 0.68 |
1 Month Change | 17.76% |
3 Month Change | 4.26% |
1 Year Change | -7.38% |
3 Year Change | -62.23% |
5 Year Change | -63.34% |
Change since IPO | 246.69% |
Recent News & Updates
Recent updates
Shareholder Returns
OZTA | DE Biotechs | DE Market | |
---|---|---|---|
7D | -3.1% | -4.3% | -2.5% |
1Y | -7.4% | -19.4% | -0.4% |
Return vs Industry: OZTA exceeded the German Biotechs industry which returned -19.4% over the past year.
Return vs Market: OZTA underperformed the German Market which returned -0.4% over the past year.
Price Volatility
OZTA volatility | |
---|---|
OZTA Average Weekly Movement | 13.7% |
Biotechs Industry Average Movement | 5.0% |
Market Average Movement | 4.9% |
10% most volatile stocks in DE Market | 9.9% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: OZTA's share price has been volatile over the past 3 months.
Volatility Over Time: OZTA's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1909 | 23,744 | Nacho Abia | www.grifols.com |
Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease. It markets diagnostic testing equipment, reagents, and other equipment; biological products; manufactures and sells plasma to third parties; and involves in research activities, as well as markets pharmaceutical products for hospital pharmacies.
Grifols, S.A. Fundamentals Summary
OZTA fundamental statistics | |
---|---|
Market cap | €5.34b |
Earnings (TTM) | €59.32m |
Revenue (TTM) | €6.59b |
101.1x
P/E Ratio0.9x
P/S RatioIs OZTA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
OZTA income statement (TTM) | |
---|---|
Revenue | €6.59b |
Cost of Revenue | €4.10b |
Gross Profit | €2.49b |
Other Expenses | €2.44b |
Earnings | €59.32m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 14, 2024
Earnings per share (EPS) | 0.087 |
Gross Margin | 37.84% |
Net Profit Margin | 0.90% |
Debt/Equity Ratio | 119.6% |
How did OZTA perform over the long term?
See historical performance and comparison